Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.36 |
| ▸ | SELE | P16581 | 2/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187170 | 0.98 | CYP1A2 (0.38) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL4479968 | 0.96 | TSPO (0.39) | TSPOKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL4188725 | 0.94 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL4193966 | 0.87 | POLB (0.43) | TSPOCYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL4193967 | 0.87 | MLYCD (0.38) | KDM4EALDH1A1ICAM1SELEVCAM1 | |
| SCHEMBL4478135 | 0.85 | ICAM1 (0.41) | KDM4ENPC1ALDH1A1LMNARAB9A | |
| SCHEMBL4191256 | 0.85 | KDM4E (0.41) | TSPOCYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL4189808 | 0.84 | KDM4E (0.41) | TSPOCYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL4191228 | 0.84 | PTGS2 (0.39) | TSPOKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL13762171 | 0.84 | ALDH1A1 (0.35) | TSPOCYP1A2CYP3A4CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576122-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | claimed |
| US-7576122-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNJ11, KCNN1 | TSPO 936/4885CYP1A2 2713/4885CYP3A4 3953/4885 |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNJ11 | TSPO 1132/4885CYP1A2 2253/4885CYP3A4 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.